Compare Stocks: BAYRY, NVO, PFE, and BMY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$13.84 -0.5%	$12.96	$7.48 ▼ $15.23	$54.67B	0.55	1.00 million shs	494,394 shs
BMY Bristol Myers Squibb	$64.70 +1.6%	$59.43	$42.52 ▼ $68.10	$130.12B	0.22	12.47 million shs	10.52 million shs
NVO Novo Nordisk A/S	$46.75 +0.8%	$47.30	$35.12 ▼ $64.16	$207.13B	0.76	12.83 million shs	10.16 million shs
PFE Pfizer	$26.80 +1.9%	$25.11	$23.58 ▼ $28.75	$149.96B	0.34	41.36 million shs	35.34 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	-2.52%	-2.32%	-1.77%	+26.11%	+83.03%
BMY Bristol Myers Squibb	+0.13%	+0.04%	+7.48%	+12.31%	+37.13%
NVO Novo Nordisk A/S	-1.48%	+4.59%	-5.60%	+1.52%	-6.57%
PFE Pfizer	-1.21%	+2.04%	+7.48%	+2.14%	+6.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$13.84 -0.5%	$12.96	$7.48 ▼ $15.23	$54.67B	0.55	1.00 million shs	494,394 shs
BMY Bristol Myers Squibb	$64.70 +1.6%	$59.43	$42.52 ▼ $68.10	$130.12B	0.22	12.47 million shs	10.52 million shs
NVO Novo Nordisk A/S	$46.75 +0.8%	$47.30	$35.12 ▼ $64.16	$207.13B	0.76	12.83 million shs	10.16 million shs
PFE Pfizer	$26.80 +1.9%	$25.11	$23.58 ▼ $28.75	$149.96B	0.34	41.36 million shs	35.34 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	-2.52%	-2.32%	-1.77%	+26.11%	+83.03%
BMY Bristol Myers Squibb	+0.13%	+0.04%	+7.48%	+12.31%	+37.13%
NVO Novo Nordisk A/S	-1.48%	+4.59%	-5.60%	+1.52%	-6.57%
PFE Pfizer	-1.21%	+2.04%	+7.48%	+2.14%	+6.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAYRY Bayer Aktiengesellschaft	3.13	Buy	N/A	N/A
BMY Bristol Myers Squibb	2.52	Moderate Buy	$66.06	2.10% Upside
NVO Novo Nordisk A/S	2.20	Hold	$64.94	38.90% Upside
PFE Pfizer	2.19	Hold	$28.28	5.50% Upside

Current Analyst Ratings Breakdown

Latest BAYRY, NVO, PFE, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$47.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/11/2026	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $31.00
8/6/2026	NVO Novo Nordisk A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$47.00
8/5/2026	NVO Novo Nordisk A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/5/2026	BMY Bristol Myers Squibb	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform ➝ Strong-Buy
8/5/2026	BMY Bristol Myers Squibb	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy
8/5/2026	BMY Bristol Myers Squibb	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/5/2026	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/5/2026	BMY Bristol Myers Squibb	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$75.00

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAYRY Bayer Aktiengesellschaft	$51.55B	1.06	$2.12 per share	6.54	$7.50 per share	1.85
BMY Bristol Myers Squibb	$49.19B	2.69	$8.27 per share	7.82	$10.93 per share	5.92
NVO Novo Nordisk A/S	$46.80B	4.46	$4.65 per share	10.06	$6.58 per share	7.11
PFE Pfizer	$62.58B	2.44	$4.43 per share	6.05	$15.00 per share	1.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAYRY Bayer Aktiengesellschaft	-$4.10B	-$0.51	N/A	10.33	4.47	-3.80%	17.00%	4.55%	N/A
BMY Bristol Myers Squibb	$7.05B	$4.54	14.25	10.08	0.17	18.87%	66.90%	14.74%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	11.43	14.12	4.30	35.36%	61.20%	21.49%	N/A
PFE Pfizer	$7.77B	$0.76	35.27	9.15	N/A	6.80%	19.63%	8.46%	N/A

Latest BAYRY, NVO, PFE, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
8/4/2026	Q2 2026	BAYRY Bayer Aktiengesellschaft	$0.23	$0.29	+$0.06	$0.07	$12.31 billion	$12.53 billion
8/4/2026	Q2 2026	PFE Pfizer	$0.6820	$0.77	+$0.0880	-$0.04	$14.40 billion	$15.03 billion
7/30/2026	Q2 2026	BMY Bristol Myers Squibb	$1.60	$2.04	+$0.44	$1.62	$11.74 billion	$12.97 billion
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAYRY Bayer Aktiengesellschaft	$0.02	0.14%	N/A	N/A	N/A
BMY Bristol Myers Squibb	$2.52	3.90%	+1.61%	55.51%	17 Years
NVO Novo Nordisk A/S	$1.75	3.74%	+21.74%	42.79%	N/A
PFE Pfizer	$1.72	6.42%	-13.20%	226.32%	16 Years

Latest BAYRY, NVO, PFE, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/24/2026	PFE Pfizer	quarterly	$0.43	7.01%	7/24/2026	7/24/2026	9/1/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.54%	8/17/2026	8/17/2026	8/25/2026
6/17/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.34%	7/2/2026	7/2/2026	8/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAYRY Bayer Aktiengesellschaft	1.06	1.05	0.70
BMY Bristol Myers Squibb	1.89	1.53	1.38
NVO Novo Nordisk A/S	0.59	0.79	0.56
PFE Pfizer	0.71	1.27	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAYRY Bayer Aktiengesellschaft	N/A
BMY Bristol Myers Squibb	76.41%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BAYRY Bayer Aktiengesellschaft	N/A
BMY Bristol Myers Squibb	0.05%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAYRY Bayer Aktiengesellschaft	88,078	3.93 billion	N/A	Not Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

BAYRY, NVO, PFE, and BMY Headlines

Recent News About These Companies

Pfizer (NYSE:PFE) Trading 1.9% Higher - What's Next?

3 hours ago | marketbeat.com

Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success

3 hours ago | finance.yahoo.com

This Healthcare Services Stock Has 37% Upside

August 13 at 12:15 PM | finance.yahoo.com

Pfizer CEO Buys $1 Million of Stock

August 13 at 12:15 PM | finance.yahoo.com

The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists

August 13 at 12:15 PM | finance.yahoo.com

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story

August 13 at 12:15 PM | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Pfizer (PFE) and Sana Biotechnology (SANA)

August 13 at 7:15 AM | theglobeandmail.com

Pfizer (NYSE:PFE) Draws Value-Focused Attention As Pharma Steadies Amid Caution

August 13 at 7:15 AM | kalkinemedia.comK

Why Is Pfizer (NYSE:PFE) Drawing Eyes as Markets Wait on Inflation Data?

August 13 at 1:28 AM | kalkinemedia.comK

Pfizer (NYSE:PFE) Draws Attention as Pharma Steadiness Meets a Cautious Market

August 13 at 1:28 AM | kalkinemedia.comK

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

August 13 at 1:28 AM | finance.yahoo.com

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

August 13 at 1:28 AM | finance.yahoo.com

Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...

August 13 at 1:28 AM | finance.yahoo.com

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

August 12 at 8:11 PM | finance.yahoo.com

Pfizer (NYSE:PFE) Shares Down 1.2% - Time to Sell?

August 12 at 5:19 PM | marketbeat.com

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

August 12 at 3:27 PM | finance.yahoo.com

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

August 12 at 12:06 PM | zacks.com

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12 at 7:51 AM | financialpost.comF

Erste Group Bank Increases Earnings Estimates for Pfizer

August 12 at 6:27 AM | marketbeat.com

Pfizer (PFE) Agreed To A $44 Million Chantix Settlement

August 12 at 5:25 AM | finance.yahoo.com

Pfizer (NYSE: PFE): Acquisitions Reshape Its Healthcare Strategy

August 11 at 10:36 PM | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BAYRY, NVO, PFE, and BMY Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$13.84 -0.07 (-0.50%)

As of 03:59 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bristol Myers Squibb NYSE:BMY

$64.69 +1.00 (+1.56%)

Closing price 03:59 PM Eastern

Extended Trading

$64.76 +0.06 (+0.09%)

As of 06:05 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Novo Nordisk A/S NYSE:NVO

$46.75 +0.36 (+0.78%)

Closing price 03:59 PM Eastern

Extended Trading

$46.58 -0.17 (-0.37%)

As of 06:06 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$26.80 +0.49 (+1.88%)

Closing price 03:59 PM Eastern

Extended Trading

$26.74 -0.07 (-0.26%)

As of 06:05 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BAYRY, NVO, PFE, and BMY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BAYRY, NVO, PFE, and BMY Earnings

Compare Dividends

Latest BAYRY, NVO, PFE, and BMY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BAYRY, NVO, PFE, and BMY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BAYRY, NVO, PFE, and BMY Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Bristol Myers Squibb NYSE:BMY

Novo Nordisk A/S NYSE:NVO

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools